G

Galapagos NV
D

GLPG

27.090
USD
1.82
(7.20%)
Market Closed
Volume
13,100
EPS
0
Div Yield
-
P/E
-28
Market Cap
1,785,151,653
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    R
    RGEN
    -17.400
    (-12.22%)
    124.960 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    More
News

Title: Galapagos NV

Sector: Healthcare
Industry: Biotechnology
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.